Welcome To Website IAS

Hot news
Achievement

Independence Award

- First Rank - Second Rank - Third Rank

Labour Award

- First Rank - Second Rank -Third Rank

National Award

 - Study on food stuff for animal(2005)

 - Study on rice breeding for export and domestic consumption(2005)

VIFOTEC Award

- Hybrid Maize by Single Cross V2002 (2003)

- Tomato Grafting to Manage Ralstonia Disease(2005)

- Cassava variety KM140(2010)

Centres
Website links
Vietnamese calendar
Library
Visitors summary
 Curently online :  51
 Total visitors :  7650854

FDA Approves First Gene Therapy using CRISPR-Cas9 to Treat Sickle Cell Disease
Wednesday, 2023/12/20 | 08:37:36

The United States Food and Drug Administration (FDA) has approved Casgevy and Lyfgenia, the first cell-based gene therapies to treat sickle cell disease (SCD). Casgevy is the first FDA-approved treatment developed using CRISPR-Cas9 genome editing technology, signaling an innovative advancement in gene therapy.

 

Casgevy, a cell-based gene therapy, is approved to treat SCD patients 12 years of age and older with recurrent vaso-occlusive crises. Casgevy is the first FDA-approved therapy that uses CRISPR-Cas9 where the patients' blood stem cells are modified using the technology. CRISPR-Cas9 can cut DNA in targeted areas to allow accurate editing (removing, adding, or replacing) of the DNA where it was cut. The modified blood stem cells are transplanted back into the patient where they attach and multiply within the bone marrow and increase the production of fetal hemoglobin (HbF)to prevent the sickling of red blood cells. Casgevy also received approval in the United Kingdom in November.

 

Lyfgenia, a cell-based gene therapy uses a lentiviral vector (gene delivery vehicle) for genetic modification and is approved for the treatment of patients 12 years of age and older with sickle cell disease and a history of vaso-occlusive events. The patient's blood stem cells are genetically modified to produce HbAT87Q, a gene-therapy-derived hemoglobin to lower the risk of sickling and occluding blood flow.

 

Sickle cell disease is a group of inherited blood disorders affecting approximately 100,000 people in the U.S. It is most common in African Americans and, while less prevalent, also affects Hispanic Americans.

 

For more details, read the FDA news release.

See https://www.isaaa.org/kc/cropbiotechupdate/article/default.asp?ID=20568

 

Back      Print      View: 158

[ Other News ]___________________________________________________
  • Egypt Holds Workshop on New Biotech Applications
  • UN Agencies Urge Transformation of Food Systems
  • Taiwan strongly supports management of brown planthopper—a major threat to rice production
  • IRRI Director General enjoins ASEAN states to invest in science for global food security
  • Rabies: Educate, vaccinate and eliminate
  • “As a wife I will help, manage, and love”: The value of qualitative research in understanding land tenure and gender in Ghana
  • CIP Director General Wells Reflects on CIP’s 45th Anniversary
  • Setting the record straight on oil palm and peat in SE Asia
  • Why insect pests love monocultures, and how plant diversity could change that
  • Researchers Modify Yeast to Show How Plants Respond to Auxin
  • GM Maize MIR162 Harvested in Large Scale Field Trial in Vinh Phuc, Vietnam
  • Conference Tackles Legal Obligations and Compensation on Biosafety Regulations in Vietnam
  • Iloilo Stakeholders Informed about New Biosafety Regulations in PH
  • Global wheat and rice harvests poised to set new record
  • GM Maize Harvested in Vietnam Field Trial Sites
  • New label for mountain products puts premium on biological and cultural diversity
  • The Nobel Prize in Physiology or Medicine 2016
  • Shalabh Dixit: The link between rice genes and rice farmers
  • People need affordable food, but prices must provide decent livelihoods for small-scale family farmers
  • GM Seeds Market Growth to Increase through 2020 Due to Rise in Biofuels Use

 

Designed & Powered by WEBSO CO.,LTD